The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Following earlier deals with Hengrui and Kelun-Biotech, Merck is turning back to China in a $2.1 billion deal centered around a KRAS-targeting medicine in preclinical development.

    Updated 9 hours ago
  • Image of prescription bottle
    Image attribution tooltip
    Permission granted by Middlesex County
    Image attribution tooltip
    Sponsored by Middlesex County, NJ

    Breakthrough therapies still need builders

    The next biopharma advantage will come from the talent and systems that turn discovery into scale.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

    Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Merck reveals study success, and possible safety worries, for eye drug hopeful

    A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

  • FDA Commissioner nominee Heidi Overton testifies before Senate committee.
    Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip
    Trump administration

    FDA nominee Overton parries vaccine questions at Senate hearing

    Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.

    FDA
  • EU Visa Mastercard card networks Europe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

    Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”

  • A hand in a blue glove holds a blood sample.
    Image attribution tooltip
    Courtesy of Grail
    Image attribution tooltip

    Grail multicancer detection test wins FDA advisers’ backing

    Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly’s latest China drug deal; Immunovant’s setback in lupus

    Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    On the same day RNAi drugmaker ADARx priced one of 2026’s biggest biotech IPOs, City Therapeutics — a maker of next-generation RNAi medicines — joined the queue.

    Updated Sept. 25, 2026
  • A laboratory scientist works with plants. Their hands are visible through several potted plants and their leaves.
    Image attribution tooltip
    Permission granted by Enveda Biosciences
    Image attribution tooltip
    Emerging biotech

    Enveda, an AI drugmaker, banks $311M in venture funding

    Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.

  • An illustration of the kidneys, colored red and blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche, Ionis RNA drug scores in kidney disease study

    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

  • President Donald Trump holds up a chart comparing drug prices and Medicare Part D costs during a healthcare affordability event in the Oval Office.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Trump administration

    A hidden tradeoff in Trump’s drug pricing deals

    The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

  • Shrugs and trees surround a large metal Amgen sign displayed outside a modern office building.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen reports a Phase 3 win with Sjögren’s drug candidate

    Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

  • A picture of tablets and injectable medicines for obesity.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares surge on updated obesity drug data

    Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

  • A micrograph of a mast cell or mastocyte, with smooth muscle fibers stained in blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Celldex sinks as safety concerns cloud immune drug results

    Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

  • A headshot of Kabir Nath, CEO of Compass Pathways.
    Image attribution tooltip
    Permission granted by Compass Pathways
    Image attribution tooltip
    Q&A // Brain drug revival

    How J&J paved the way for Compass’ coming psychedelic drug launch

    In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’

    Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

  • A close-up of a person's brown eye.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beacon eye gene therapy hits mark in late-stage study

    Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo talks up drug launches in effort to win back investors

    At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: GSK’s China deals, the $300M IPO club and selling the news

    The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Xenon shares fall following depression trial pause

    The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

    Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Electra amasses $350M in biotech’s latest big IPO

    Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lisata deal propels Marea’s drug pipeline to Wall Street

    Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    North Immunology joins biotech reverse merger boom with Aethlon deal

    Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.